AIMS: Disease management programs (DMP) for @entity6 ( @entity6 ) or @entity301 ( @entity301 ) address the treatment of @entity4977 . The current registry aimed to compare drug utilization, lipid lowering effects and further outcomes of outpatients at high cardiovascular risk in DMP for @entity6 or @entity301 compared to @entity1 in routine care (no-DMP). METHODS: This was a prospective non-interventional registry with a 1 year follow-up which enrolled consecutive @entity1 with known @entity6 and/or any @entity455 on @entity3413 40   mg monotherapy, to document lipid target achievement in clinical practice in Germany according to existing guidelines. Drug use (maintenance, add-on, switch, discontinuation) and other components of care were upon the discretion of the treating physician. RESULTS: Of a total of 12,154 @entity1 (mean age 65.8 years, 61.2% males), 3273 were in DMP @entity301 , 3265 in DMP @entity6 and 1760 in DMP @entity301   +   @entity6 . In DMP @entity1 compared to no-DMP @entity1 , comorbidities/risk factors were more frequent. More @entity1 in the DMP groups attained the target level of low density lipoprotein (LDL-C) <70   mg/dl (1.8   mmol/l) at baseline (8.5% DMP vs. 5.7% no-DMP), at 6 month (10.3% vs. 7.4%) and 12 month follow-up (10.1% vs. 7.1%). @entity165 absorption inhibitors were added in 16% of the @entity1 at the end of the baseline or at the follow-up visits, while @entity6817 treatment (including mean dose) remained largely unchanged. Target achievement rates were highest for all time points in the DMP @entity301   +   @entity6 group. With respect to limitations, this study was restricted to @entity4977 as qualifying diagnosis and @entity3413 as qualifying treatment, which is a potential cause of selection bias. Information on non-pharmacological measures was not collected, and the 12-month follow-up period was relatively short. CONCLUSION: @entity1 in DMP compared to those not in DMP achieved better LDL-C lowering and higher control rates, but overall lipid target achievement rates need to be improved. Longer-term observations are needed to corroborate these findings.

Better lipid target achievement for secondary prevention through disease management programs for @entity6 and XXXX in clinical practice in Germany.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity455 :: ('MESH:D014652', 'Disease') :: ['vascular disease'] @entity3413 :: ('MESH:D019821', 'Chemical') :: ['simvastatin'] @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetes mellitus', 'DM'] @entity301 :: ('MESH:D003327', 'Disease') :: ['CHD', 'coronary heart disease'] @entity4977 :: ('MESH:D052439', 'Disease') :: ['lipid disorders'] @entity6817 :: ('D019821', 'Chemical') :: ['statin'] @entity165 :: ('MESH:D002784', 'Chemical') :: ['Cholesterol']
@entity301 :: (MESH:D003327,Disease) :: ['coronary heart disease']
